{
    "clinical_study": {
        "@rank": "136384", 
        "brief_summary": {
            "textblock": "To determine the potential effects of 28 days of nevirapine treatment on the steady-state\n      pharmacokinetics of nelfinavir and of stavudine (d4T), and to further evaluate the\n      pharmacokinetics of nevirapine in combination with nelfinavir, and d4T compared to the\n      historical controls treated with nevirapine but without nelfinavir or d4T. To determine the\n      efficacy of long-term combination therapy of nevirapine, nelfinavir and d4T on viral load in\n      patients who are non-nucleoside reverse transcriptase inhibitor (NNRTI) and protease\n      inhibitor naive, and have <= 6 months prior d4T exposure at the time of screening."
        }, 
        "brief_title": "The Safety and Effectiveness of Nevirapine Plus Nelfinavir in HIV-1 Infected Patients Who Have Taken Stavudine", 
        "condition": "HIV Infections", 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome"
            ]
        }, 
        "detailed_description": {
            "textblock": "The trial is an open-label study in patients with HIV-1 infection who are naive to treatment\n      with NNRTI and protease inhibitor classes of antiretroviral drugs and have <= 6 months prior\n      exposure to d4T at the time of screening. Part I of this trial is an investigation of\n      potential pharmacokinetic interaction between nevirapine and nelfinavir in HIV-1-infected\n      adults treated with d4T. Part II is an investigation of the long-term antiviral activity of\n      the combination of nevirapine and nelfinavir on viral load as measured by HIV-1 RNA."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Patients must have:\n\n          -  Documented HIV infection.\n\n          -  CD4+ cell count >= 100 cells/mm3.\n\n          -  Plasma HIV-1 RNA >= 5000 copies/ml.\n\n        Prior Medication:\n\n        Allowed:\n\n        Previous antiretroviral therapy with zidovudine, lamivudine, didanosine, and\n        dideoxycytidine.\n\n        Exclusion Criteria\n\n        Co-existing Condition:\n\n        Patients with the following symptoms and conditions are excluded:\n\n          -  Malabsorption, severe chronic diarrhea, or the inability to maintain adequate oral\n             intake.\n\n          -  Undergoing treatment for an active infection.\n\n          -  Hepatic insufficiency due to cirrhosis.\n\n          -  Renal insufficiency.\n\n             1. Systemic treatment with corticosteroids or drugs known to be hepatic enzyme\n             inducers or inhibitors within 14 days of entry. Substances in these categories\n             include:\n\n          -  macrolide antibiotics (erythromycin, clarithromycin, azithromycin, dirithromycin),\n             azole antifungals (ketoconazole, fluconazole, itraconazole), rifampin, rifabutin, and\n             phenytoin.\n\n          -  Previous exposure to non-nucleoside reverse transcriptase inhibitors (NNRTIs) such as\n             delavirdine, loviride, DMP 266, or nevirapine and/or protease inhibitors (PI) such as\n             saquinavir, ritonavir, indinavir, and nelfinavir.\n\n          -  > 6 months previous exposure to d4T.\n\n          -  Investigational drugs within 30 days of first dose of study medication.\n\n          -  Any antineoplastic agent within 12 weeks before starting study medication.\n\n        Radiotherapy, other than local skin radiotherapy treatment, within 12 weeks prior to\n        study.\n\n        1. History of intravenous drug abuse or alcohol or substance abuse considered by the\n        Investigator and BIPI Medical Monitor to be a significant impairment to health and\n        compliance.\n\n          -  Heavy smokers (e.g., > 20 cigarettes per day)."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": "24", 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002381", 
            "org_study_id": "200F", 
            "secondary_id": "1100.1224"
        }, 
        "intervention": [
            {
                "intervention_name": "Nelfinavir mesylate", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "Nevirapine", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "Stavudine", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Nevirapine", 
                "Stavudine", 
                "Nelfinavir"
            ]
        }, 
        "keyword": [
            "HIV-1", 
            "Drug Therapy, Combination", 
            "Nevirapine", 
            "Stavudine", 
            "RNA, Viral", 
            "Nelfinavir", 
            "Anti-HIV Agents", 
            "Viral Load"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "San Francisco", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94109"
                    }, 
                    "name": "Saint Francis Mem Hosp / HIV Care Unit"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Providence", 
                        "country": "United States", 
                        "state": "Rhode Island", 
                        "zip": "02908"
                    }, 
                    "name": "Roger Williams Med Ctr"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "An Investigation of the Potential Pharmacokinetic Interaction Between Nevirapine (Viramune) and Nelfinavir (Viracept) and the Efficacy of This Combination Therapy in HIV-1 Infected Adults Treated With Stavudine [d4T] (Zerit)", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002381"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Boehringer Ingelheim", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Endpoint Classification: Safety Study, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2002"
    }, 
    "geocoordinates": {
        "Roger Williams Med Ctr": "41.824 -71.413", 
        "Saint Francis Mem Hosp / HIV Care Unit": "37.775 -122.419"
    }
}